Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
688331.SS
HOLDFLAGRemeGen Co., Ltd. · Healthcare · China · $9.7B · Avg Vol: $174M/d
RemeGen has a promising ADC pipeline, but as a pre-profit biotech, it suffers from high cash burn and lacks the established cash flows and high ROIC of a true compounder.
COMPANY DESCRIPTION
RemeGen Co., Ltd. is a leading clinical-stage biopharmaceutical company that discovers and develops innovative biologics, focusing on antibody-drug conjugates (ADCs) and fusion proteins for oncology and autoimmune diseases. Its competitive moat is anchored by globally recognized assets like Telitacicept and Disitamab Vedotin, the latter of which secured a major out-licensing deal with Seagen. The company stands out as a premier, vertically integrated Chinese biotech player with global commercial potential.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 113M | 159M | 253M | 479M | 61.6% |
| EPS | -0.28 | -0.41 | -0.40 | 0.19 | — |
| Shares | 544M | 544M | 544M | 564M | +3.6% |
| Debt | 24M | 186M | 395M | 325M | 137.2% |
| Equity | 736M | 508M | 294M | 533M | -10.2% |
| Op CF | -187M | -222M | -174M | 8M | — |
| Inv CF | -124M | -121M | -27M | -30M | — |
| Fin CF | 359M | 145M | 206M | 82M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688331.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688331.SS | RemeGen Co., Ltd.(you) | $9.7B | 48 | HOLD |
| 002653.SZ | Haisco Pharmaceutical Group Co., Ltd. | $8.5B | 56 | HOLD |
| 300759.SZ | Pharmaron Beijing Co., Ltd. | $6.8B | 44 | HOLD |
| 1801.HK | Innovent Biologics, Inc. | $18.5B | 49 | HOLD |
| 688428.SS | InnoCare Pharma Limited | $6.4B | 40 | HOLD |
| 2696.HK | Shanghai Henlius Biotech, Inc. | $4.8B | 45 | HOLD |
| 6990.HK | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | $13.7B | 60 | HOLD |
| 600161.SS | Beijing Tiantan Biological Products Co., Ltd. | $4.0B | 46 | HOLD |
| 9926.HK | Akeso, Inc. | $13.9B | 31 | SELL |
| 002252.SZ | Shanghai RAAS Blood Products Co., Ltd. | $5.2B | 34 | SELL |
Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 52.9%